Skip to main content
ICU logo

SeaStar Medical Holding Corporation (ICU) Stock: Price, Forecast & Analyst Target

SeaStar Medical Holding Corporation (ICU) — MoonshotScore 20/100 (Weak band), calculated Oct 4, 2026. Price $4.69 (+25.07%), as of the Oct 2, 2026 trading session; market cap $13.3M.

Educational signal · not a buy or sell recommendation · How to read this

$4.69 +$0.94 (+25.07%) Market Cap $13.3M

SeaStar Medical Holding Corporation · ICU · NASDAQ

SeaStar Medical Holding Corporation is a medical device company developing extracorporeal therapies to treat hyperinflammation and cytokine storm in critically ill patients. Its focus areas include acute kidney injury, cardiorenal syndrome, myocardial stunning, and hepatorenal syndrome, utilizing novel solutions to target effector cells.

Price as of Oct 2, 2026

Key Statistics

20 of 100

MoonshotScore v2 · SeaStar Medical Holding (ICU)

Weak
Business Quality Poor (13)
Financial Safety Strained (34)
Valuation Bubble (6)
Growth Durability Growing (67)
Momentum Quiet (55)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a strained balance sheet and an expensive valuation. Business Quality: Poor; Financial Safety: Strained; Valuation: Bubble; Growth Durability: Growing; Momentum: Quiet.

  • quarterly revenue $615,000 (Q2 FY2026, quarter ended Jun 2026)
  • EPS beat 6 of 8
  • Altman Z -28.70 · Piotroski F 2

Holding back: weak fundamentals, balance-sheet strain, a rich price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ICU (29 recorded, newest six shown)
RecordedScoreBand
23Weak
20Weak
20Weak
20Weak
20Weak
20Weak

The score was 20 in the stored Oct 3, 2026 snapshot and remains 20 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Financial Safety +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$4.69
Change on the day+25.07%
52-week range$2.07 – $7.35
Market capitalisation$13.3M
Shares traded on the day519.7K

Price & events

Council Score · weighted blend of 2 available disciplines

Council score for SeaStar Medical Holding (ICU): Split View

37/100 · D

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Growth Durability Moderate
Momentum Neutral
Business Quality Negative
Financial Safety Weak
Valuation Negative

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Oct 4, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Strong
ROE Negative
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Simons-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Oct 4, 2026, except a card that shows its own read date.

Watch the ICU film — every key number, told as a short cinematic story

~2 min · open the film

1 · What is it?

What is SeaStar Medical Holding (ICU), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. SeaStar Medical Holding Corporation (ICU) is listed on NASDAQ. It employs 18 people and is led by Eric Schlorff. In Q2 FY2026 it reported revenue of $615,000 and net income of -$4M. The market values it at $13.3M.

2 · Latest results

What do the latest results show for SeaStar Medical Holding (ICU)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $615,000. Against analyst estimates the company has EPS beat 6 of 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$615,000-$4M-$0.91 (diluted)
Q1 FY2026$495,000-$4M-$0.09 (diluted)
Q4 FY2025$420,000-$3M-$0.14 (diluted)
Q3 FY2025$183,000-$3M-$1.32 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for SeaStar Medical Holding (ICU)?

Short answer

What is holding it back is weak fundamentals, balance-sheet strain, a rich price. The distress and quality screens read Altman Z -28.70 · Piotroski F 2. Trailing ratios: current ratio 1.89 · earnings yield -84.7%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -28.70 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at SeaStar Medical Holding (ICU)?

Short answer · as of

Current published price targets run low $8.00 · high $8.00 · consensus $8.00 · median $8.00 against a quoted price of $4.69 (as of Oct 2, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does SeaStar Medical Holding compare with its peers?

Short answer

SeaStar Medical Holding's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Theravance Biopharma, Inc. (TBPH) Same industry, near in market value$17.03 Sep 23, 2026$883M95 5-pillar Oct 4, 2026
CorMedix Inc. (CRMD) Same industry, near in market value$7.19 Oct 2, 2026$564M94 5-pillar Oct 4, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$47.15 Oct 2, 2026$872M93 5-pillar Oct 4, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.99 Oct 2, 2026$591M91 5-pillar Oct 4, 2026
MiMedx Group, Inc. (MDXG) Same industry, near in market value$4.59 Oct 2, 2026$669M88 5-pillar Oct 4, 2026
Arbutus Biopharma Corporation (ABUS) Same industry, near in market value$4.45 Oct 2, 2026$879M85 5-pillar Oct 4, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$17.08 Oct 2, 2026$90.6M83 5-pillar Oct 4, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$9.75 Oct 2, 2026$88.2M79 5-pillar Oct 4, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$9.75 Oct 2, 2026$690M77 5-pillar Oct 4, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$4.49 Oct 2, 2026$184M76 5-pillar Oct 4, 2026
Niagen Bioscience Inc (NAGE) Same industry, near in market value$2.79 Oct 2, 2026$222M69 5-pillar Oct 4, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$10.94 Oct 2, 2026$626M68 5-pillar Oct 4, 2026
SeaStar Medical Holding (ICU) — this page$4.69$13.3M20

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$8.00 – $8.00
Consensus target
$8.00
Median target
$8.00

Consensus record · Captured .

Measured against a quoted price of $4.69 (as of Oct 2, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 18, 2026

Transactions
7
Identified insiders
7
Purchases
1
Sales
0
Other transactions
6

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

What has been published about SeaStar Medical Holding (ICU)?

Read these with our analysis →

SeaStar Medical Holding Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the ICU research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ICU?

ICU carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is ICU a good stock to buy?

Stock Expert AI does not rate ICU buy, sell or hold. SeaStar Medical Holding Corporation carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ICU stock price today?

The last price recorded on this page for SeaStar Medical Holding Corporation (ICU) is $4.69, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ICU price target?

The analyst consensus price target for SeaStar Medical Holding Corporation (ICU) is $8.00 (range $8.00 to $8.00, median $8.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What does SeaStar Medical Holding Corporation do?

SeaStar Medical Holding Corporation is a medical device company that develops and commercializes innovative extracorporeal therapies. These therapies are designed to treat hyperinflammation and cytokine storm, severe immune responses that cause tissue damage in critically ill patients.

What are the key factors to evaluate for ICU?

SeaStar Medical Holding Corporation (ICU) holds a MoonshotScore in the low range. Analysts target $8.00 (+71%). SeaStar Medical is actively developing extracorporeal therapies across multiple critical care indications, including acute kidney injury, cardiorenal syndrome, myocardial stunning, and hepatorenal syndrome, demonstrating a diversified pipeline strategy. Not financial advice.

How frequently does ICU data refresh on this page?

ICU's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ICU's recent stock price performance?

SeaStar Medical Holding Corporation (ICU) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel extracorporeal therapies targeting effector cells for hyperinflammation. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ICU overvalued or undervalued right now?

SeaStar Medical Holding Corporation (ICU) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $8.00 (+71%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources — records for every figure on this page (21 figures)

The 21 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.

"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.

FMP — 13 facts from Financial Modeling Prep endpoint families

FMP facts used on this page
Fact IDFactValue as shownAs ofTierSource
px.lastLatest provided price$4.69FMPFinancial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T20:54:57.942Z.
px.changeChange on the day+25.07%FMPFinancial Modeling Prep (FMP) · quote
px.mcapMarket capitalisation$13.3MFMPFinancial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-04T20:54:56.593Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares.
px.change_absChange on the day, in dollars+$0.94FMPFinancial Modeling Prep (FMP) · quote
fin.q_revenueRevenue, Q2 FY2026$615,000FMPFinancial Modeling Prep (FMP) · income statement (quarterly)
px.volumeShares traded on the day519.7KFMPFinancial Modeling Prep (FMP) · quote
fin.q_incomeNet income, Q2 FY2026-$4MFMPFinancial Modeling Prep (FMP) · income statement (quarterly)
fin.q_tableQuarterly income statement4 quarters through Q2 FY2026FMPFinancial Modeling Prep (FMP) · income statement (quarterly), as filed
earn.ptStored analyst price targetslow $8.00 · high $8.00 · consensus $8.00 · median $8.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied
earn.pt_rangeAnalyst price target, low to high$8.00 – $8.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied
earn.pt_consensusConsensus analyst price target$8.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied
earn.pt_medianMedian analyst price target$8.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied
own.insidersInsider transactions via FMP7 transactions · 1 purchases, 0 sales, 6 other transactions · 7 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Aug 18, 2026FMPFinancial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

UNRECORDED — 6 facts from stored observations whose source was not recorded

UNRECORDED facts used on this page
Fact IDFactValue as shownAs ofTierSource
earn.historyReported versus estimated, recent quartersEPS beat 6 of 8UNRECORDEDStored earnings-history observation — Captured 2026-09-16 · Expired observation
fin.scoresDistress and quality screensAltman Z -28.70 · Piotroski F 2UNRECORDEDStored financial-scores observation — Captured 2026-10-03 · Expired observation
px.range5252-week range$2.07 – $7.35UNRECORDEDStored company-profile observation — Captured 2026-10-04
id.employeesEmployees18UNRECORDEDStored company-profile observation — Captured 2026-10-04
id.ceoChief executiveEric SchlorffUNRECORDEDStored company-profile observation — Captured 2026-10-04
fin.ratiosReturn and yield ratios (trailing twelve months)current ratio 1.89 · earnings yield -84.7%—UNRECORDEDStored key metrics — Date unknown

OURS — 2 facts from Stock Expert AI's own score and rank

OURS facts used on this page
Fact IDFactValue as shownAs ofTierSource
ours.moonshotMoonshotScore v220 of 100 · Weak · pillars 13 / 34 / 6 / 67 / 55OURSStock Expert AI MoonshotScore v2 engine
ours.moonshot_changeMoonshotScore movement20 (stored snapshot Oct 3, 2026) → 20 (current publication computed Oct 4, 2026) (0)OURSStock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive.
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.